{"answer":{"query":"Xpovio","resolved_as":"applications","packages":9,"applications":["NDA212306"],"identity":{"application_numbers":["NDA212306"],"marketing_categories":["NDA"],"labelers":[{"text":"KARYOPHARM THERAPEUTICS","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2019-07-10","latest":"2026-01-05","packages_with_a_start_date":9}},"generic_entry":[{"application":"NDA212306","date":"2035-08-14","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10519139","productNo":"001"},"latest_patent_expiry":"2035-08-14","latest_exclusivity_expiry":"2027-12-18","dated_barriers":83,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":11,"exclusivities_listed":6,"fact_id":"434cd6ad2305f70d74b64173"}],"label_history":{"events_total":7,"non_cmc_events":6,"counts_by_class":{"EFFICACY":3,"LABELING":3},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA212306","submission_no":18,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-04-23","documents":[{"type":"Letter","date":"2026-05-04","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/212306Orig1s018ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-05-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212306s018lbl.pdf","untrusted":true}}],"fact_id":"bc4053de032337594ff8b993"},{"application":"NDA212306","submission_no":16,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-09-26","documents":[{"type":"Label","date":"2025-09-26","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212306s016lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-09-30","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/212306Orig1s016ltr.pdf","untrusted":true}}],"fact_id":"a59d9fdddbd1d1c4e54f6e26"},{"application":"NDA212306","submission_no":11,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-07-15","documents":[{"type":"Letter","date":"2022-07-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212306Orig1s011ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-07-19","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212306s011lbl.pdf","untrusted":true}}],"fact_id":"0aefb0a76ec34f3a1cc33fd3"},{"application":"NDA212306","submission_no":10,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-03-28","documents":[{"type":"Letter","date":"2022-03-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212306Orig1s010ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-03-29","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212306s010lbl.pdf","untrusted":true}}],"fact_id":"b759a804eb4c638173c29d02"},{"application":"NDA212306","submission_no":5,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2020-12-18","documents":[{"type":"Label","date":"2020-12-18","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s005lbl.pdf","untrusted":true}},{"type":"Letter","date":"2020-12-22","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212306Orig1s005ltr.pdf","untrusted":true}}],"fact_id":"d62b69f29c17434ddb369d4d"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":6,"te_code_counts":{"NOT_PROVIDED":6},"marketing_status_counts":{"Prescription":6},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA212306","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XPOVIO","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"40MG","untrusted":true}},{"application":"NDA212306","product_no":"006","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XPOVIO","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"80MG","untrusted":true}},{"application":"NDA212306","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XPOVIO","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"60MG","untrusted":true}},{"application":"NDA212306","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XPOVIO","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"20MG","untrusted":true}},{"application":"NDA212306","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XPOVIO","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"50MG","untrusted":true}},{"application":"NDA212306","product_no":"005","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XPOVIO","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"10MG","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":3,"next_package_termination_dates":["2027-02-08","2027-02-28","2027-05-31"],"packages_with_future_termination_date":3,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"spending":{"reported_under":{"generic":{"text":"Selinexor","untrusted":true},"brand":{"text":"Xpovio","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":48683550.49,"claims":2177,"beneficiaries":919,"average_spending_per_claim_usd":22362.678222,"fact_id":"994b99d50a488dec95b1b66d"},{"year":2021,"gross_spending_usd":69551731.92,"claims":3072,"beneficiaries":1157,"average_spending_per_claim_usd":22640.537734,"fact_id":"5453b7d2d09990d2a6871e36"},{"year":2022,"gross_spending_usd":86816590.79,"claims":3585,"beneficiaries":1219,"average_spending_per_claim_usd":24216.622257,"fact_id":"0aab2712d859a68b83357cbe"},{"year":2023,"gross_spending_usd":85562245.68,"claims":3219,"beneficiaries":1117,"average_spending_per_claim_usd":26580.380764,"fact_id":"9ef4d1b80d053d9ba4257e41"},{"year":2024,"gross_spending_usd":98217996.64,"claims":3428,"beneficiaries":1103,"average_spending_per_claim_usd":28651.690968,"fact_id":"2500990538c69d43c94751d9"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"Selinexor; selinexor","untrusted":true},"designation_count":7,"approved_count":3,"recent":[{"designated":"2022-05-26","use":{"text":"Treatment of Myelofibrosis","untrusted":true},"status":"Designated","sponsor":{"text":"Karyopharm Therapeutics, Inc.","untrusted":true},"approved":false},{"designated":"2021-12-02","use":{"text":"Treatment of Glioblastoma (aka glioblastoma multiforme)","untrusted":true},"status":"Designated","sponsor":{"text":"Karyopharm Therapeutics, Inc.","untrusted":true},"approved":false},{"designated":"2016-07-07","use":{"text":"Treatment of soft tissue sarcoma","untrusted":true},"status":"Designated","sponsor":{"text":"Karyopharm Therapeutics, Inc.","untrusted":true},"approved":false},{"designated":"2015-01-05","use":{"text":"Treatment of multiple myeloma","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Karyopharm Therapeutics, Inc.","untrusted":true},"approved":true},{"designated":"2015-01-05","use":{"text":"Treatment of multiple myeloma","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Karyopharm Therapeutics, Inc.","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"e8400cd5c02154c9a017fec3"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"}},"receipts":[{"fact_id":"d58b7a5052edc1b37f730589","field":"ndc.listing","entity":"ndc:72237010103"},{"fact_id":"864eb60a26d4c279fab98275","field":"ndc.listing","entity":"ndc:72237010104"},{"fact_id":"3c2b36535f7c5378cb43db08","field":"ndc.listing","entity":"ndc:72237010202"},{"fact_id":"434cd6ad2305f70d74b64173","field":"drug.generic_entry_earliest","entity":"application:NDA212306"},{"fact_id":"629720dd93371e84b15c6433","field":"drug.patent","entity":"application:NDA212306"},{"fact_id":"2a7571f5a9a1a2c87694db64","field":"drug.exclusivity","entity":"application:NDA212306"},{"fact_id":"bc4053de032337594ff8b993","field":"drug.label_event","entity":"application:NDA212306"},{"fact_id":"a59d9fdddbd1d1c4e54f6e26","field":"drug.label_event","entity":"application:NDA212306"},{"fact_id":"0aefb0a76ec34f3a1cc33fd3","field":"drug.label_event","entity":"application:NDA212306"},{"fact_id":"b759a804eb4c638173c29d02","field":"drug.label_event","entity":"application:NDA212306"},{"fact_id":"d62b69f29c17434ddb369d4d","field":"drug.label_event","entity":"application:NDA212306"},{"fact_id":"e36f292eb5b2d11ad6f5e555","field":"drug.marketing_status","entity":"application:NDA212306"},{"fact_id":"d64f8aafe669d060b3d2b335","field":"drug.marketing_status","entity":"application:NDA212306"},{"fact_id":"8eab544c39a8f2e0f5e59630","field":"drug.marketing_status","entity":"application:NDA212306"},{"fact_id":"5dacc90d582c199f78170dd6","field":"drug.marketing_status","entity":"application:NDA212306"},{"fact_id":"48bceac3ce70e7c83ca7741b","field":"drug.marketing_status","entity":"application:NDA212306"},{"fact_id":"301c352caf1b121cd752630c","field":"drug.marketing_status","entity":"application:NDA212306"},{"fact_id":"50d1281db6db26ee3fecc0fe","field":"ndc.product","entity":"ndc:72237010103"},{"fact_id":"eb1d9750be286b756eaecbe5","field":"ndc.product","entity":"ndc:72237010206"},{"fact_id":"11798e7014de157b34d3f144","field":"ndc.product","entity":"ndc:72237010207"},{"fact_id":"994b99d50a488dec95b1b66d","field":"drug.partd_spending","entity":"drug:selinexor|xpovio"},{"fact_id":"5453b7d2d09990d2a6871e36","field":"drug.partd_spending","entity":"drug:selinexor|xpovio"},{"fact_id":"0aab2712d859a68b83357cbe","field":"drug.partd_spending","entity":"drug:selinexor|xpovio"},{"fact_id":"9ef4d1b80d053d9ba4257e41","field":"drug.partd_spending","entity":"drug:selinexor|xpovio"},{"fact_id":"2500990538c69d43c94751d9","field":"drug.partd_spending","entity":"drug:selinexor|xpovio"},{"fact_id":"e8400cd5c02154c9a017fec3","field":"drug.orphan_designation","entity":"drug:selinexor"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"trials","reason":"no ClinicalTrials.gov record set for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"},{"code":"NO_DATA","field":"medicaid_state_utilization","reason":"no CMS State Drug Utilization figure for this drug's packages is in the edition (suppressed, out of scope or unreported)"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}